At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS
In Brief
A Phase 3 clinical trial evaluating LAU-7b for 3 cycles, LAU-7b for 1 cycle, then placebo, and 1 other intervention for Long COVID. Completed, enrolled 272 participants across 5 sites.
Detailed Summary
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
Study Details
Timeline
Interventions
Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of 14 days.
One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of 14 days.
Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of 14 days